Sec. 4. Advancing the field of regenerative medicine
326 words·~1 min read·
/bill/116/s/4672/is/section-4A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 402 of the Public Health Service Act ( 42 U.S.C. 282 ) is amended by adding at the end the following: The Director of NIH shall, as appropriate, continue to consult with the directors of relevant institutes and centers of the National Institutes of Health, other relevant experts from such institutes and centers, and relevant experts within the Food and Drug Administration, to further the field of regenerative medicine using adult stem cells, including autologous stem cells, therapeutic tissue engineering products, human cell and tissue products, human gene therapies, and genetically modified cells. .
Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that assesses the workforce related to the C.W. Bill Young Cell Transplantation Program established under section 379 of the Public Health Service Act ( 42 U.S.C. 274k ). The report shall include— an overview of the current employment levels, in both commercial and academic settings, for— positions necessary for the collection and transplantation of stem cell therapeutics, including bone marrow and cord blood; and positions in the field of regenerative medicine using adult stem cells and related to product development; the identification of gaps, if any, in the projected workforce capacity for— positions described in paragraph (1)(A); and the field of regenerative medicine using adult stem cells, including workforce gaps related to the development of new cellular therapies using adult stem cells; an overview of the availability of training programs related to the development, refinement, and utilization of adult stem cells, including training on good manufacturing practices for such activities, and the performance of such programs; and recommendations, if any, for improving the workforce capacity related to— the positions described in paragraph (1)(A); or the field of regenerative medicine using adult stem cells.
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources